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Abstract
Background: In addition to the biochemical components secreted in bile, aquaporin (AQP) water
channels exist in hepatocyte membranes to form conduits for water movement between the sinusoid and
the bile canaliculus. The aim of the current study was to analyse AQP 9 expression and localization in
human hepatocellular carcinoma (HCC) and non-tumourigenic liver (NTL) tissue from patients undergoing
hepatic resection.
Methods: Archived tissue from 17 patients was sectioned and analysis performed using an antibody
raised against AQP 9. Slides were blind-scored to determine AQP 9 distribution within HCC and NTL
tissue.
Results: Aquaporin 9 was predominantly expressed in the membranes of hepatocytes and demon-
strated zonal distribution relative to hepatic sinusoid structure in normal liver. In HCC arising in the
absence of cirrhosis AQP 9 remained membrane-localized with zonal distribution in the majority of NTL.
By contrast, AQP 9 expression was significantly decreased in the HCC mass vs. pair-matched NTL. In
HCC in the presence of cirrhosis, NTL was characterized by extensive AQP 9 staining in the membrane
in the absence of zonal distribution and AQP 9 staining in NTL was significantly greater than that observed
in the tumour mass.
Conclusions: These data demonstrate that human HCC is characterized by altered AQP 9 expression
and AQP 9 localization in the NTL mass is dependent on underlying liver pathology. Given the central role
of AQPs in normal liver function and the potential role of AQPs during transformation and progression,
these data may prove valuable in future diagnostic and/or therapeutic strategies.
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Introduction
The synthesis, secretion and modification of bile by hepatocytes
represent a primary physiological function of the liver. For bile
synthesis to occur, hepatocytes must demonstrate cell polarity in
which distinct basolateral and canalicular membranes exist.1 The
biochemical components of bile are actively transported from the
hepatocyte across the canalicular membrane into the bile canali-
culus.2,3 In addition to the biochemical constituents, ª95–98% of
bile is water.2,4 Water is able to cross the plasma membrane of cells
in one of two ways: directly through the lipid bilayer (a slow,
unregulated process), or via proteinacious water channels termed
aquaporins (AQPs).5,6 Within the hepatocyte at least three distinct
AQP populations have been identified at the mRNA and protein
level: AQPs 0, 8 and 9,1,7,8 whereas AQP 11 has been reported at the
mRNA level.9 Under normal conditions AQPs 0, 8 and 9 are con-
stitutively expressed, AQPs 0 and 8 are located (predominantly)
intracellularly and AQP 9 is localized, for the most part, to the
basolateral membrane.4,8,10,11 However, following appropriate
stimulation, AQP 8 translocates to the canalicular membrane1,8,12*Both authors contributed equally to this article
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and, in conjunction with basolateral AQP 9, may act to form a
conduit for rapid water movement from the hepatic sinusoid
to the bile canaliculus during the process of bile synthesis and
modification.7,8
Hepatocellular carcinoma (HCC) represents one of the most
common gastrointestinal malignancies diagnosed worldwide
and accounts for >80% of all primary liver tumours.13–15 Unlike in
other common cancers, familial markers for HCC development
are rare; HCCmost commonly arises following exposure to one or
more ‘environmental’ factors, the most common of which are viral
hepatitis infection, aflatoxins (naturally occurring mycotoxins
produced by species of Aspergillus) and/or chronic alcohol con-
sumption.14,16,17 Despite the varied nature of these risk factors,
underlying hepatic cirrhosis following exposure represents the
most common precursor to subsequent HCC development.15,18
Unlike normal liver cells, the transformed cells that comprise
HCC undergo cellular end-stage de-differentiation, are character-
ized by altered responsiveness to mitogenic and apoptotic stimuli
and, to varying degrees, fail to perform the normal physiological
functions of the parent hepatocytes, including bile synthesis and
secretion.13,14,18
In a previous study carried out by our laboratory, we reported
that AQP 8 and 9 expression is significantly decreased in a rat
model of HCC, an event that correlates with altered responsive-
ness to exogenous and endogenous apoptotic stimuli.19 However,
this model of HCC was generated by inoculating transformed
hepatic epithelial cells (H4IIE) into the parenchyma of healthy
animals, a technique that results in reproducible tumour forma-
tion in the absence of changes to the underlying integrity of the
liver.19,20 By contrast, the underlying pathology from which HCC
arises in humans is varied.13,14,18 The aims of the current study
were to analyse AQP 9 expression and cellular localization in
human HCC samples and adjacent non-tumourigenic liver
(NTL) tissue from patients who had undergone HCC resection
therapy.
Materials and methods
Tissue specimens
Paraffin-embedded surgical specimens from the pathological files
of 17 patients undergoing hepatic resection at the Carolinas
Medical Center were obtained, following institutional review
board guidelines. In two cases normal liver, in the absence of
hepatic tumours, was obtained from non-transplanted livers.
Of the 15 samples with HCC, seven had underlying micro (six of
seven) or macro (one of seven) hepatic cirrhosis and eight had
HCC in the setting of ostensibly normal liver architecture. Repre-
sentative tissue sections were used for immunohistochemical
(IHC) study and the diagnosis for each lesion was confirmed.
Clinicopathological data for HCC patients are shown in Table 1.
The stage of disease was determined after the surgical resection of
the tumour and the histological grade was determined according
to the degree of tumour differentiation.
Immunohistochemical study
Formalin-fixed paraffin-embedded tissues were cut into 5-mm
sections and dried onto Superfrost-plus glass slides (Fisher
Scientific, Inc., Pittsburgh, PA, USA). Sections were then depar-
affinized with standard xylene and hydrated through graded
alcohols into water. Antigen retrieval was performed using
citrate buffer and heating (10 min; 100 °C). Slides were placed
into a 3% hydrogen peroxide blocking medium (20 min) and
allowed to react with a custom rabbit IgG anti-human AQP 9
polyclonal antibody (1:500 dilution, 30 min) raised and previ-
ously characterized by our laboratory.19 Immunodetection was
performed using an avidin-biotin complex system in accordance
with the manufacturer’s instructions (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). Slides were counterstained with hae-
matoxylin (Sigma-Aldrich Corp., St Louis, MO, USA) and dehy-
drated through graded alcohols and mounted with a cover-slip.
Appropriate positive controls were used (normal liver, n = 2) and
negative controls were performed by omitting antiserum from
the primary incubation. Specimen slides were viewed randomly,
without clinical data, by two of the authors (SP and AMS).
Scoring of slides for zonal distribution and staining intensity was
based upon a predetermined scale created using representative
tissue sections (Fig. 1).
Immunofluorescent histochemical analysis
Formalin-fixed paraffin-embedded tissues were cut into 5-mm
sections, mounted on glass slides, deparaffinized, hydrated and
subjected to antigen retrieval, blocking and reaction with the
rabbit IgG anti-human AQP 9 polyclonal antibody (1:500 dilu-
tion, 30 min), as previously. Detection was performed using an
Alexa488-conjugated goat anti-rabbit secondary antibody (Invit-
rogen Corp., Carlsbad, CA, USA), counterstained with DAPI
(Invitrogen Corp.) and dehydrated through graded alcohols
prior to cover-slip mounting with an anti-fade medium (Invit-
rogen Corp.). The sections were examined by laser scanning con-
focal microscopy (Olympus America, Inc., Melville, NY, USA),
each channel recorded independently and superimposed images
generated.
Statistical analysis
Scoring data from two independent analysts for five random fields
(HCC and non-HCC tissue) were combined and averaged for
each sample. Statistical analysis was performed using GraphPad
Prism software (GraphPad Software, Inc., San Diego, CA, USA). A
P-value of <0.05 was considered significant.
Results
Aquaporin 9 expression is predominantly
membrane-localized and demonstrates zonal
distribution in normal liver
Immunohistochemical analysis was performed on sections of
normal human liver (NL) without tumour masses (n = 2). Using
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this approach, AQP 9 protein was readily detected and, at
low magnification, it was apparent that AQP 9 was not evenly
distributed throughout the liver and, instead, a clear lobular-zonal
distribution was identified (Z3 >> Z2 > Z1; Fig. 2). At higher
magnification AQP 9 was observed to be (predominantly) local-
ized in the plasmamembrane of hepatocytes and, to a significantly
lower degree, within the cytoplasm (3.65  0.60 vs. 0.82  0.1,
membrane vs. cytoplasm; values are means of five separate fields
scored independently by two different investigators, n = 2 separate
samples) (Fig. 2).
AQP 9 expression in HCC samples in the absence of
underlying hepatic cirrhosis
In patients in whom HCC arose in the absence of underlying
cirrhosis, the NTL tissue was not distinguishable from normal
liver architecture observed in the absence of HCC tumours.At low
magnification in NTL tissue, four of seven specimens demon-
strated moderate to high zonal distribution of AQP 9 as detected
by IHC and immunofluorescent histochemistry (IFHC) (Z3 >>
Z2 > Z1; Fig. 3a, b), whereas in the remaining three specimens,
zonal distribution was either low or not apparent. It is of note that
two of the three specimens in which NTL zonal distribution was
not apparent represented the largest HCC samples resected within
this study group (mean tumour diameters: 130 mm and
150 mm).
At higher magnification, AQP 9 detection occurred to a signifi-
cantly higher degree in the membrane than the cytoplasm of NTL
in all samples analysed (2.87 1.05 vs. 0.64 0.44,membrane vs.
cytoplasm; values are means of five separate fields scored inde-
pendently by two different investigators, n = 7 separate samples; P
< 0.05) (Fig. 3). Analysis of the HCC region of the specimens
demonstrated significantly lower AQP 9 expression in the mem-
brane of cells within the HCC mass vs. NTL (1.01  0.71 vs. 2.87
 0.71; values are means of five separate fields scored indepen-
dently by two different investigators, n = 7 separate samples;
P < 0.05) (Fig. 3c). By contrast, whereas cytoplasmic staining was
significantly lower than membrane in all instances, no significant
differences in cytoplasmic AQP 9 staining were detected between
HCC and NTL (Fig. 3c).
a)
b)
0 1 2 3 4 5
Z3
Z2
Z1
Figure 1 Standards used for determining zonal staining and degree of staining for aquaporin (AQP) 9. (a) Representative immunohistochemi-
cal (IHC) image of normal liver (NL) section following IHC staining using an anti-human AQP 9 antibody. Superimposed are the representative
lobular structure (dashed lines) and relative zones within the lobule (solid lines) used as a standard for analysis of tissue. (b) Different levels
of AQP 9 membrane staining were assigned numerical scores of 0–5 based on stain intensity. These standards were used for subsequent
blind scoring of diseased tissue
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AQP 9 expression in HCC samples in the setting of
underlying hepatic cirrhosis
In patients in whom HCC arose in the setting of underlying
cirrhosis, the NTL mass was clearly distinguishable from normal
liver architecture by the presence of scar tissue and fibrous septae
that encompassed nodules of hepatocytes (Fig. 4a, b). At lowmag-
nification, following staining for AQP 9, the NTLmass was further
distinguishable by the complete absence of zonal AQP 9 staining
in the cirrhotic tissue (Fig. 4a, b). In all cases, a clear distinction
could be made between the non-tumourigenic hepatic mass and
the HCC tumour, with the HCC demonstrating significantly
lower AQP 9 expression than the surrounding cirrhotic tissue
(Fig. 4a, b) (3.40 0.98 vs. 0.84 0.41, NTL vs. HCC; values are
means of five separate fields scored independently by two different
investigators, n = 8 separate samples; P < 0.05; Fig. 4c). At higher
magnification analysis, the NTL tissue demonstrated extensive
membrane staining for AQP 9 and showed that the AQP 9 staining
was significantly higher in the membrane than the cytoplasm
(3.40  0.46 vs. 0.98  0.40, membrane vs. cytoplasm; values are
means of five separate fields scored independently by two different
investigators, n = 8 separate samples; P < 0.05; Fig. 4). In the HCC
mass, a non-significant trend was observed for decreased cytoplas-
mic AQP 9 staining vs. cytoplasmic staining in the surrounding
cirrhotic liver tissue (decreased in six of eight cases, approximately
equal staining in one of eight cases and increased in one of eight
cases in HCC vs. NTL). Of further note, the case in which AQP 9
staining was increased in HCC cytoplasm (vs. the NTL) repre-
sented the only sample in which the patient tested normal for
serum a-fetoprotein and was the smallest tumour resected within
this group (mean tumour diameter: 41 mm).
Analysis of AQP 8 expression
In addition to AQP 9, AQP 8 has been identified as another physi-
ologically important AQP in hepatocytes. Studies using rodent
models have identified that AQP 8 exists (predominantly in the
cytoplasmic regions) in hepatocytes and, following appropriate
stimuli, translocates to the canalicular membrane. Using commer-
cially available antibodies, we next sought to determine the
relative expression and localization of AQP 8 in HCC and NTL
sections. Despite varying the IHC techniques, we were unable to
reproducibly detect AQP 8 protein expression in either HCC or
NTL, nor within sections prepared from the same sample (data
not shown).
Discussion
Previous studies using rodent liver tissue identified AQP 0, 8 and
9 expression within hepatocytes at the mRNA and protein
levels,1,12,21 and AQP 11 at the mRNA level only.9 In these model
systems, the authors report uneven levels of expression of AQPs 0,
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Figure 2 Normal liver in the absence of hepatocellular carcinoma (HCC) is characterized by zonal aquaporin (AQP) 9 distribution and is
predominantly localized to the plasma membrane. (a) Representative immunohistochemical (IHC) images of normal liver (NL) section
following IHC staining using an anti-human AQP 9 antibody. Note the zonal distribution (upper panel) and the membrane localization (lower
panel). (b) Cumulative scoring analysis of membrane vs. cytoplasmic staining for AQP 9 in hepatocytes in NL. Values are means  standard
error of the mean of five separate fields scored independently by two different investigators; n = 2 separate samples. *P < 0.05
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Figure 3 Hepatocellular carcinoma (HCC)in the absence of underlying cirrhosis is characterized by decreased aquaporin (AQP) 9 expression.
(a) Representative immunohistochemical (IHC) images of HCC non-tumour liver (NTL) sections following IHC staining using an anti-human
AQP 9 antibody. Note the continued zonal distribution (left and middle panels) in the NTL that occurred in four of seven samples analysed
and the relative absence of AQP 9 staining in the tumour (left panel). (b) Representative immunofluorescent histochemical (IFHC) images of
HCC and NTL sections following IFHC staining using an anti-human AQP 9 antibody and detection with a Fluro488 labelled secondary
antibody (green). Sections were counterstained with DAPI (blue) for nuclear localization. The HCC/NTL margin is identified by a dashed line.
(c) Cumulative scoring analysis of membrane vs. cytoplasmic staining for AQP 9 in NTL vs. HCC. Values are means  standard error of the
mean of five separate fields scored independently by two different investigators; n = 7 separate samples. *P < 0.05
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Figure 4 Hepatocellular carcinoma (HCC)in the presence of underlying cirrhosis is characterized by decreased aquaporin (AQP) 9 expres-
sion. (a) Representative immunohistochemical (IHC) images of HCC non-tumour liver (NTL) sections following IHC staining using an
anti-human AQP 9 antibody. Note the formation of hepatocyte-containing nodules bordered by fibrous septae in the NTL and lack of zonal
distribution of AQP 9 (left and middle panels) in the NTL that occurred in all eight of the samples analysed coupled with the relative absence
of AQP 9 staining in the tumour (left panel). (b) Representative immunofluorescent histochemical (IFHC) images of HCC and NTL sections
following IFHC staining using an anti-human AQP 9 antibody and detection with a Fluro488 labelled secondary antibody (green). Sections
were counterstained with DAPI (blue) for nuclear localization. (c) Cumulative scoring analysis of membrane vs. cytoplasmic staining for AQP
9 in NTL vs. HCC. Values are means standard error of the mean of five separate fields scored independently by two different investigators;
n = 8 separate samples. *P < 0.05
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8 and 9, whereby AQP 8 is expressed to a greater degree than AQP
9, which is in turn expressed to a greater degree than AQP 0.1
Researchers using mouse and rat tissue reported AQPs 0 and 8 to
be most strongly expressed in hepatocytes that surround the
central vein, and AQP 9 to be uniformly distributed throughout
the liver.1 In addition, AQPs 0 and 8 appear to be predominantly
located intracellularly in these rodent models, whereas AQP 9 is
most strongly detected in the basal membrane.1 By contrast with
these findings, our analysis of normal human liver in the absence
of HCC burden demonstrated clear zonal distribution of AQP 9
within the sinusoid, where staining for AQP 9 occurred in Z3 >>
Z2 > Z1. However, as with rodent hepatic tissue, the cellular dis-
tribution of AQP 9 in normal human liver was localized to the
membrane of hepatocytes in human liver samples and membrane
expression was significantly greater than that detected in the cyto-
plasmic region.
Within the healthy liver the role of AQPs in normal and abnor-
mal hepatic function during disease pathogenesis is a relatively
new, although intense, area of research interest.4,8 To date consid-
erable evidence exists suggesting a role for cyclic-AMP (cAMP) in
regulating AQP 8 translocation from cytoplasmic compartments
to the canalicular membrane during bile synthesis in response to
enteric stimulation (glucagon).1,12,22,23 By contrast, relatively little
is known about the regulation and function of AQP 9. The (appar-
ently) constitutive expression of AQP 9 and (predominant) local-
ization to the basolateral membrane in hepatocytes has led to
speculation that, in conjunction with AQP 8 translocation to the
canalicular membrane, these two AQPs act to form a conduit to
allow the rapid passage of water between the hepatic sinusoid and
the bile canaliculus.4,8 However, unlike AQP 8, AQP 9 (along with
AQPs 3, 7 and 10) belongs to a family of AQPs termed aquaglyc-
eroporins because of their ability to transport specific small,
uncharged molecules through the pore structure of the protein,
including glycerol and urea.24,25 Hence it is increasingly speculated
that AQP 9 may play a central role during hepatocyte glycerol
uptake, especially during ‘starvation states’ in which glycerol
deriving from adipose lipolysis is a major substrate for hepatic
gluconogenesis.8,26,27 Similarly, the constitutive basolateral expres-
sion and ability of AQP 9 to transport urea has also led to specu-
lation that these channel structures are further involved in
metabolic regulation.4,8
Given the potential range of roles that AQP 9 may play in
normal hepatic physiology, it was unsurprising to us that AQP 9
expression in NTL in the absence of underlying cirrhosis (i.e.
ostensibly normal hepatic architecture) resembled that observed
in normal liver in the absence of tumour burden in four of the
seven cases analysed (i.e. zonal distribution coupled with mem-
brane localization). Of interest, it was noted that in two of seven
cases in which zonal distribution no longer occurred (in the NTL
of HCC-burdened patients in the absence of cirrhosis) these were
the largest tumour masses resected in which, one might predict,
the highest degree of compromise of normal hepatic function
might be found.More striking were the differences in AQP expres-
sion in livers of patients with underlying cirrhosis compared
with those without. No zonal distribution of AQP 9 was apparent
in any of the samples analysed. Rather, extensive membrane-
localized AQP 9 expression was detected throughout the NTL and
was localized to the nodules of hepatocytes located between fib-
rogenic septae.
Given the clear differences in AQP location detected in the NTL
of cirrhotic and non-cirrhotic patients, we next sought to analyse
the expression of AQP 9 in HCC masses. These data revealed
significantly lower AQP 9 expression in HCC compared with NTL
of patients with or without underlying cirrhosis. Furthermore, no
significant differences were observed between AQP 9 localized to
the membrane compared with the cytoplasm in the tumour mass.
Initially, these observations may seem logical: as well as no longer
responding to normal mechanisms that regulate cell proliferation,
end-stage transformed, tumourigenic HCC cells are also charac-
terized by de-differentiation and failure, to varying degrees, to
perform the functions of the parent cell population (hepato-
cytes).14,15 Hence, given the emerging role(s) of AQP 9 in normal
hepatic physiology, the absence of AQP 9 in cancerous cells may
simply reflect the failure of these cells to participate in normal
hepatic functions or homeostasis. However, studies in colorectal
cancer tissue report increased expression of AQPs 1 and 5, neither
of which are detected in non-transformed cells, in the early stages
of tumourigenesis and subsequently throughout the course of
the disease.28 In this instance, the authors speculate that increased
AQP expression may lead to transformed cells gaining an advan-
tage during the increased rates of replication and enhanced meta-
bolic demands of these cells.28 In previous research by our group,
we reported that, in rodent models, HCC tumourigenic tissue and
cells demonstrate decreased AQP 9 expression compared with
NTL.19 In this instance we also demonstrated that decreased AQP
protein expression correlates with increased resistance to apop-
totic stimuli as a result of the inability of cells to undergo the
highly conserved biological process termed the apoptotic volume
decrease (AVD) that is a prerequisite for subsequent apoptotic
progression.29–31
In light of these data it is tempting to speculate on a potentially
significant role for AQP 9 during both the tumourigenic and
progression stages of HCC. That is, during initial transformation
the cell no longer responds to normal signalling mechanisms that
regulate fundamental hepatocyte features and functions, includ-
ing bile synthesis and secretion. In this instance, failure to produce
defined polar membranes may lead to diminished AQP 9 expres-
sion. Subsequently, these cells may no longer be susceptible to
apoptotic deletion as a result of the absence of membrane-
localized AQP 9 and a failure to undergo the AVD,29,30 a feature
that will confer inherent advantages for transformed cell survival
during progression.
In conclusion, the current study demonstrates a significant dif-
ference in AQP 9 expression and localization in NTL depending
upon the underlying pathology of the patient (i.e. cirrhotic vs.
non-cirrhotic). However, regardless of underlying hepatic
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pathology, HCC demonstrates significantly decreased AQP 9
expression compared with NTL.At present the precise role of AQP
9 (and other AQP forms normally expressed in hepatocytes)
during cell transformation and HCC progression remain to be
fully elucidated. However, the data presented in this study indicate
that increasing the sample size for further analysis and identifying
suitable antibodies for use in IHC analysis of human specimens
warrants further investigation.
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